Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The early-stage pipeline for amyotrophic lateral sclerosis ...
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive neurodegenerative disease. It affects your nerves and muscle tissue and worsens over time, eventually becoming fatal.
It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative ...
Amyotrophic Lateral Sclerosis, commonly known as ALS, is an incurable neurodegenerative disease that affects all voluntary muscles in the body leading to paralysis and breathing difficulties. Eye ...
Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results